KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.

J Clin Oncol · 2025-Jul · PMID 40215429

Panel B提取完成待 EXE 对齐验证

OS

FIG 2. OS of sotorasib-panitumumab versus investigator's choice. (A) Kaplan-Meier curves of OS for sotorasib 960 mg-panitumumab (full analysis set). (B) Kaplan-Meier curves of OS for sotorasib 240 mg-panitumumab (full analysis set). (C) Forest plot of sotorasib 960 mg-panitumumab treatment effect on OS in subgroup analyses. (D) Forest plot of sotorasib 240 mg-panitumumab treatment effect on OS in subgroup analyses. The dashed horizontal gray line indicates the median value. Vertical bars indicate censoring. Stratified Cox hazard ratio and stratified log-rank P value for sotorasib-panitumumab versus investigator's choice are provided. The intention-to-treat population included all patients who underwent random assignment. Hazard ratio was not estimated when there were fewer than 10 patients in either treatment arm in a subgroup. HR, hazard ratio; NE, not estimable; OS, overall survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.58
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-23T17:42:11+00:00